Skip to main content
. Author manuscript; available in PMC: 2015 Dec 31.
Published in final edited form as: Int J Tuberc Lung Dis. 2012 Jun 11;16(8):1069–1074. doi: 10.5588/ijtld.11.0696

Table 3.

Characteristics of patients who developed XDR-TB and patients who did not after ≥ 6 months of follow-up after outcomes were reported

Patients who developed XDR-TB during treatment (n = 10)
n (%)		 Patients who developed XDR-TB after treatment (n = 13)
n (%)		 Patients who did not develop XDR-TB after ≥6 months of follow-up (n = 102)
n (%)
Male 8 (80) 12 (92) 83 (81)
Prisoners 1 (10) 2 (15) 5 (5)
Alcohol or drug addiction 4 (40) 10 (77) 29 (28)
Patients treated with FLDs before MDR-TB treatment 1 (10) 1 (8) 22 (22)
Patients treated with SLDs before MDR-TB treatment 5 (50) 9 (69) 48 (47)
Outcome of DOTS-Plus program
 Died 4 (40) NA NA
 Defaulted or transferred out 1 (10) 5 (38) 16 (16)
 Failed 4 (40) 6 (46) 12 (12)
 Cured 1 (10) 2 (15) 69 (68)
 Completed treatment 0 0 5 (5)

XDR-TB = extensively drug-resistant tuberculosis; FLD = first-line drug; MDR-TB = multidrug-resistant tuberculosis; SLD = second-line drug; NA = not applicable.